Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss

Fertil Steril. 2009 May;91(5):1963-5. doi: 10.1016/j.fertnstert.2008.01.007. Epub 2008 Mar 12.

Abstract

Oral contraceptive pretreatment facilitated scheduling of pure FSH/GnRH antagonist cycles but in a small subset of patients was associated with low serum LH levels, reduced ovarian response, and early pregnancy loss. Supplementation with LH could be examined as a possible way to improve cycle outcome.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Spontaneous / etiology
  • Adult
  • Chorionic Gonadotropin / pharmacology*
  • Contraceptives, Oral / pharmacology*
  • Embryo Implantation
  • Female
  • Follicle Stimulating Hormone / pharmacology*
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors*
  • Gonadotropin-Releasing Hormone / pharmacology
  • Humans
  • Luteinizing Hormone / blood*
  • Ovary / drug effects*
  • Ovulation Induction*
  • Pregnancy
  • ROC Curve
  • Recombinant Proteins / pharmacology

Substances

  • Chorionic Gonadotropin
  • Contraceptives, Oral
  • Recombinant Proteins
  • Gonadotropin-Releasing Hormone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • ganirelix